Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Description:
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.
Sponsor:
NovartisContacts:
Novartis Pharmaceuticalsnovartis.email@novartis.com
1-888-669-6682
Government Study Link:
NCT07006727 - Click here to see study onClinicalTrials.gov
[225Ac]Ac-ETN029
- DLL3
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
Not yet provided. Contact Novartis Pharmaceuticals for more information.
1-888-669-6682
novartis.email@novartis.com
